KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Gains from Sales and Divestitures (2017 - 2023)

Biolife Solutions (BLFS) has disclosed Gains from Sales and Divestitures for 7 consecutive years, with $346184.0 as the latest value for Q1 2023.

  • On a quarterly basis, Gains from Sales and Divestitures rose 58.6% to $346184.0 in Q1 2023 year-over-year; TTM through Mar 2023 was $346184.0, a 58.6% increase, with the full-year FY2022 number at $569535.0, up 50.47% from a year prior.
  • Gains from Sales and Divestitures was $346184.0 for Q1 2023 at Biolife Solutions, down from $569535.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $569535.0 in Q4 2022 to a low of $53026.0 in Q1 2020.
  • A 5-year average of $235018.9 and a median of $218280.0 in 2022 define the central range for Gains from Sales and Divestitures.
  • Biggest YoY gain for Gains from Sales and Divestitures was 219.29% in 2022; the steepest drop was 5.62% in 2022.
  • Biolife Solutions' Gains from Sales and Divestitures stood at $125818.0 in 2019, then surged by 66.0% to $208858.0 in 2020, then surged by 81.22% to $378502.0 in 2021, then skyrocketed by 50.47% to $569535.0 in 2022, then plummeted by 39.22% to $346184.0 in 2023.
  • Per Business Quant, the three most recent readings for BLFS's Gains from Sales and Divestitures are $346184.0 (Q1 2023), $569535.0 (Q4 2022), and $448056.0 (Q3 2022).